Compare Illinois Tool Works Inc. (ITW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs TransMedics Group Inc — how do they compare? Illinois Tool Works Inc. trades at $293.57 (market cap $83.49B), while TransMedics Group Inc trades at $87.33 (market cap $3.10B). The key difference: Illinois Tool Works Inc. is far larger — about 26.9× TransMedics Group Inc's market cap, and Illinois Tool Works Inc. pays a 2.35% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| ITW | TMDX | |
|---|---|---|
Market Cap | $83.49B | $3.10B |
Sector | Industrials | Technology |
52-Week High | $299.60 | $150.42 |
52-Week Low | $241.07 | $61.99 |
Enterprise Value | $92.34B | $3.49B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $293.66, down 0.29% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 19.39% net income margin and 104.65% ROE, though valuations appear elevated at P/E 26.55 and P/B 28.85. Recent Q2 2026 earnings beat expectations at $2.84 EPS, and management raised full-year guidance amid manufacturing sector recovery. The company announced a 7% dividend increase and $6 billion share repurchase program in August 2026.
Outlook remains positive with analyst consensus target of $314.25 offering 7% upside potential. Key catalysts include continued manufacturing recovery and margin expansion from the 80/20 program. Risks include premium valuation concerns and potential organic sales declines masked by currency gains. Institutional sentiment is mixed with 21% buy ratings versus 32% sell recommendations.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
